Cargando…
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-...
Autores principales: | Zhu, Yuan Xiao, Shi, Chang-Xin, Bruins, Laura A., Wang, Xuewei, Riggs, Daniel L., Porter, Brooke, Ahmann, Jonathan M., de Campos, Cecilia Bonolo, Braggio, Esteban, Bergsagel, P. Leif, Stewart, A. Keith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370766/ https://www.ncbi.nlm.nih.gov/pubmed/30741931 http://dx.doi.org/10.1038/s41408-019-0173-0 |
Ejemplares similares
-
Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020) -
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019) -
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017) -
Transcriptional profiles define drug refractory disease in myeloma
por: Zhu, Yuan Xiao, et al.
Publicado: (2022) -
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
por: Lopez-Girona, A, et al.
Publicado: (2012)